China’s biotechnology sector is experiencing an explosive resurgence, with its performance this year surpassing even the much-hyped artificial intelligence wave. After years of subdued investor interest, the sector is seeing a dramatic reversal, driven by landmark licensing deals, blockbuster IPOs, and growing global recognition of China’s research capabilities.
Since the beginning of 2025, the Hang Seng Biotech Index has soared over 60%, outstripping the 17% rally in China’s tech stocks fueled by DeepSeek’s AI breakthrough. This surge is largely credited to a series of multi-billion-dollar deals that mark a turning point in how Chinese biotech innovation is perceived globally.
One such deal came in May when Pfizer announced a $1.25 billion licensing agreement with Shenyang-based 3SBio for an experimental cancer drug—alongside a $100 million equity investment. Just weeks later, Bristol-Myers Squibb revealed a deal worth up to $11.5 billion to license a cancer therapy originally developed by China’s Biotheus and sublicensed to Germany’s BioNTech.
These high-profile agreements signal not only growing confidence in the quality of Chinese biotech R&D but also the sector’s ability to scale globally. According to Yiqi Liu, senior analyst at Exome Asset Management, “China biotech is no longer just an emerging story. It is now a disruptive force reshaping global drug innovation. The science is real, the economics are compelling, and the pipeline is starting to deliver.”
Record Gains and Investor Momentum
Investor excitement has driven stratospheric gains in several biotech firms. 3SBio’s shares are up 283%, making it one of the top-performing biotech stocks globally. RemeGen, another Chinese drug developer specializing in antibody therapeutics, has risen over 270% amid speculation of further licensing deals with multinationals.
New listings have added further fuel. Duality Biotherapeutics, focused on next-generation cancer therapies, saw its shares more than double on debut in April and have since risen 189%. Meanwhile, Jiangsu Hengrui Pharmaceuticals, China’s largest pharmaceutical company by market value, jumped 25% on its May IPO, with shares now up 31%.
Behind the surge is a swelling tide of pharmaceutical mergers and acquisitions. In Q1 alone, China accounted for more than half of global pharma M&A volume, with deals involving local players reaching $36.9 billion, double that of the same period last year.
Not Without Skepticism
Despite the momentum, not everyone is convinced the rally is sustainable. Analysts at Bank of America, led by Ethan Cui, caution that some investors are cashing out, while others are rotating into more stable, dividend-yielding healthcare names. There’s also skepticism about whether recent mega-deals are repeatable or represent a peak in valuation optimism.
Yet, structural tailwinds continue to favor the sector. Geopolitical and macroeconomic shifts have also resulted in a wave of talent repatriation, with top-tier researchers returning to China to expand domestic R&D capabilities and fast-track innovation.
According to Nicholas Chui, equity fund manager at Franklin Templeton, this return of human capital is creating significant long-term value for the industry and reinforcing China’s leadership in biotech development.
The Road Ahead
According to Dong Chen, chief Asia strategist at Pictet Wealth Management, Chinese biotech is having its “own DeepSeek moment,” referring to the AI app that catalyzed a rally in tech stocks earlier this year. While tech continues to attract mainstream attention, the biotech boom is quickly becoming one of the year’s most defining investment narratives.
With strong fundamentals, growing international validation, and a reinvigorated talent pool, China’s biotech sector is no longer a speculative bet. It’s emerging as a cornerstone of the next wave in global healthcare innovation.
What an exciting time for China’s biotech sector! The surge in innovation and investor interest is truly fascinating. It seems like the next wave of global healthcare is just around the corner!